Cargando…

Targeting CD33 for acute myeloid leukemia therapy

BACKGROUND: The aim of this study was to analyze the level of CD33 expression in patients with newly diagnosed AML and determine its correlation with clinical characteristics. METHODS: Samples were collected for analysis from AML patients at diagnosis. We evaluated the level of CD33 expression by fl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jingjing, Tong, Jiayin, Yang, Haiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722076/ https://www.ncbi.nlm.nih.gov/pubmed/34980040 http://dx.doi.org/10.1186/s12885-021-09116-5

Ejemplares similares

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022)

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
por: Bäumer, Nicole, et al.
Publicado: (2022)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
por: Laszlo, George S., et al.
Publicado: (2016)

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33(+) Acute Myeloid Leukemia
por: Dutour, A., et al.
Publicado: (2012)

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
por: Mamolo, Carla, et al.
Publicado: (2020)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
por: Molica, Matteo, et al.
Publicado: (2021)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

Immunosuppressive role of CD11b(+)CD33(+)HLA‐DR(−) myeloid‐derived suppressor cells‐like blast subpopulation in acute myeloid leukemia
por: Hyun, Shin Young, et al.
Publicado: (2020)

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2021)

An Overview of Targeted Therapies in Acute Myeloid Leukemia
por: Turkalj, Sven, et al.
Publicado: (2023)

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2017)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
por: Garg, Ravendra, et al.
Publicado: (2020)

Resistance to targeted therapies in acute myeloid leukemia
por: Mecklenbrauck, Rabea, et al.
Publicado: (2022)

Advances in targeted therapy for acute myeloid leukemia
por: Yu, Jifeng, et al.
Publicado: (2020)

Targeted Therapy Development in Acute Myeloid Leukemia
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

Molecular landscape and targeted therapy of acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2018)

Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis
por: Farber, Meike, et al.
Publicado: (2021)

Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia
por: Qin, Lei, et al.
Publicado: (2016)

Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia
por: Khan, Naeem, et al.
Publicado: (2016)

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia
por: Lo, Tsun-Ho, et al.
Publicado: (2019)

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia
por: Obszański, Piotr, et al.
Publicado: (2022)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

Recent advances in targeted therapies in acute myeloid leukemia
por: Bhansali, Rahul S., et al.
Publicado: (2023)

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19(+) CD33(+) leukemia cells
por: Roskopf, Claudia C., et al.
Publicado: (2016)

CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia
por: Yakymiv, Yuliya, et al.
Publicado: (2019)

Extraordinarily elevated CD33 expression in CD56(+)CD3(–) cells in the bone marrow of a patient with relapsed acute myeloid leukemia: a case report
por: Wang, Dongyao, et al.
Publicado: (2021)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation
por: Abadir, Edward, et al.
Publicado: (2019)

A general view of CD33(+) leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy
por: Fathi, Ezzatollah, et al.
Publicado: (2020)

Precision therapy for acute myeloid leukemia
por: Yang, Xue, et al.
Publicado: (2018)

CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML)
por: Jiang, Yongfang, et al.
Publicado: (2017)

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT
por: O Marani, L., et al.
Publicado: (2022)

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
por: Schneider, Dina, et al.
Publicado: (2018)

Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin
por: Wijnen, Noa E, et al.
Publicado: (2023)

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia
por: Minagawa, Kentaro, et al.
Publicado: (2016)

Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

89723 CD105-targeted CAR T cells for the treatment of acute myeloid leukemia
por: Lontos, Konstantinos, et al.
Publicado: (2021)

CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia
por: Kaito, Yuta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ar5cragt41i61j82e1nh1541o8